<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">15198516</PMID>
      <DateCompleted>
        <Year>2004</Year>
        <Month>08</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1522-1059</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>5</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2003</Year>
              <Month>Nov</Month>
              <Day>05</Day>
            </PubDate>
          </JournalIssue>
          <Title>AAPS pharmSci</Title>
          <ISOAbbreviation>AAPS PharmSci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Hydroxyzine from topical phospholipid liposomal formulations: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model.</ArticleTitle>
        <Pagination>
          <StartPage>E28</StartPage>
          <MedlinePgn>E28</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Hydroxyzine, an effective but sedating H1-antihistamine is given orally to treat allergic skin disorders. This study was performed to assess the peripheral H(1)-antihistaminic activity and extent of systemic absorption of hydroxyzine from liposomes applied to the skin. Using L-alpha-phosphatidylcholine (PC), small unilamellar vesicles (SUVs) and multilamellar vesicles (MLVs) containing hydroxyzine were prepared. Hydroxyzine in Glaxal Base (GB) was used as the control. Using a randomized, crossover design, each formulation, containing 10 mg of hydroxyzine, was applied to the shaved backs of 6 rabbits (3.08 +/- 0.05 kg). Histamine-induced wheal tests and blood sampling were performed at designated time intervals up to 24 hours. Compared with baseline, hydroxyzine from all formulations significantly suppressed histamine-induced wheal formation by 75% to 95% for up to 24 hours. Mean maximum suppression, 85% to 94%, occurred from 2 to 6 hours, with no differences among the formulations. The areas of plasma hydroxyzine concentration versus time area under the curve (AUCs) from PC-SUV and PC-MLV, 80.1 +/- 20.8 and 78.4 +/- 33.9 ng/mL/h, respectively, were lower than that from GB, 492 +/- 141 ng/mL/h (P &lt; or =.05) over 24 hours. Plasma concentrations of cetirizine arising in-vivo as the active metabolite of hydroxyzine, from PC-SUV, PC-MLV, and GB, were similar with AUCs of 765 +/- 50, 1035 +/- 202, and 957 +/- 227 ng/mL/h, respectively (P &lt; or =.05). Only 0.02% to 0.06% of the initial hydroxyzine dose remained on the skin after 24 hours. In this model, hydroxyzine from SUV and MLV had excellent topical H1-antihistaminic activity, and minimal systemic exposure occurred. Cetirizine formed in-vivo contributed to some of H1-antihistaminic activity.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Elzainy</LastName>
            <ForeName>Abeer A W</ForeName>
            <Initials>AA</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Pharmacy, University of Manitoba, Winnipeg, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gu</LastName>
            <ForeName>Xiaochen</ForeName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Simons</LastName>
            <ForeName>F Estelle R</ForeName>
            <Initials>FE</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Simons</LastName>
            <ForeName>Keith J</ForeName>
            <Initials>KJ</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2003</Year>
          <Month>11</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>AAPS PharmSci</MedlineTA>
        <NlmUniqueID>100897065</NlmUniqueID>
        <ISSNLinking>1522-1059</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006634">Histamine H1 Antagonists</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008081">Liposomes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010743">Phospholipids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>30S50YM8OG</RegistryNumber>
          <NameOfSubstance UI="D006919">Hydroxyzine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>820484N8I3</RegistryNumber>
          <NameOfSubstance UI="D006632">Histamine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002626" MajorTopicYN="N">Chemistry, Pharmaceutical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006632" MajorTopicYN="N">Histamine</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006634" MajorTopicYN="N">Histamine H1 Antagonists</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006919" MajorTopicYN="N">Hydroxyzine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006967" MajorTopicYN="N">Hypersensitivity</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008081" MajorTopicYN="N">Liposomes</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010743" MajorTopicYN="N">Phospholipids</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011817" MajorTopicYN="N">Rabbits</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011897" MajorTopicYN="N">Random Allocation</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2004</Year>
          <Month>6</Month>
          <Day>17</Day>
          <Hour>5</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2004</Year>
          <Month>8</Month>
          <Day>4</Day>
          <Hour>5</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2004</Year>
          <Month>6</Month>
          <Day>17</Day>
          <Hour>5</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">15198516</ArticleId>
        <ArticleId IdType="pmc">PMC2750990</ArticleId>
        <ArticleId IdType="doi">10.1208/ps050428</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Simons FER. H1-receptor antagonists: safety issues. Ann Allergy Asthma Immunol. 1999;83:481–488.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10582735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reynolds JEF.  Martindale the Extra Pharmacopoeia. 30th ed. London, UK: The Pharmaceutical Press; 1993. </Citation>
        </Reference>
        <Reference>
          <Citation>Maghraby GMM, Williams AC, Barry BW. Oestradiol skin delivery from ultradeformable liposomes: refinement of surfactant concentration. Int J Pharm. 2000;196:63–74. doi: 10.1016/S0378-5173(99)00441-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0378-5173(99)00441-X</ArticleId>
            <ArticleId IdType="pubmed">10675708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ganesan MG, Weiner ND, Flynn GL, Ho NFH. Influence of liposomal drug entrapment on percutaneous absorption. Int J Pharm. 1984;20:139–154. doi: 10.1016/0378-5173(84)90225-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0378-5173(84)90225-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Niemiec SM, Latta JM, Ramachandran C, Weiner ND, Roessler BJ. Perifollicular transgenic expression of human Interleukin-1 receptor antagonist protein following topical application of novel liposome-plasmid DNA formulation in-vivo. J Pharm Sci. 1997;86:701–708. doi: 10.1021/js9604873.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/js9604873</ArticleId>
            <ArticleId IdType="pubmed">9188052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fleisher D, Niemiec SM, Oh CK, Hu Z, Ramachandran C, Weiner N. Topical delivery of growth hormone releasing peptide using liposomal systems: an in-vitro study using hairless mouse skin. Life Sci. 1995;57:1293–1297. doi: 10.1016/0024-3205(95)02086-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0024-3205(95)02086-X</ArticleId>
            <ArticleId IdType="pubmed">7674821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Egbaria K, Ramachandran C, Kittayanond D, Weiner N. Topical delivery of liposomally encapsulated interferon evaluated by invitro diffusion studies. Antimicrob Agents Chemother. 1990;34:107–110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC171529</ArticleId>
            <ArticleId IdType="pubmed">1691613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mezei M.  Liposomes in the topical application of drugs: a review. In: Gregoriadis G, editor. Liposomes as Drug Carriers, Recent Trends and Progress. New York, NY: John Wiley and Sons; 1988. </Citation>
        </Reference>
        <Reference>
          <Citation>Krowczynski L, Stozek T. Liposomes as drug-carriers in the transdermal therapy. Pharmazie. 1984;39:627–629.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6505001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel HM. Liposomes as a controlled-release system. Biochem Soc Trans. 1985;13:513–516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3894112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Price CI, Horton JW, Baxter CR. Liposome delivery of aminoglycosides in burn wounds. Surg Gynecol Obstet. 1992;174:414–418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1570621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Price CI, Horton JW, Baxter CR. Topical liposomal delivery of antibiotics in soft tissue infection. J Surg Res. 1990;49:174–178. doi: 10.1016/0022-4804(90)90258-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0022-4804(90)90258-4</ArticleId>
            <ArticleId IdType="pubmed">2381207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vyas SP, Singh R, Asati RK. Liposomally encapsulated diclofenac for sonophoresis induced systemic delivery. J Microencapsul. 1995;12:149–154. doi: 10.3109/02652049509015285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/02652049509015285</ArticleId>
            <ArticleId IdType="pubmed">7629657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Ridy MS, Khalil RM. Free versus liposome-encapsulated lignocaine hydrochloride topical applications. Pharmazie. 1999;54:682–684.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10522272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin GP.  Phospholipids as skin penetration enhancers. In: Walters KA, Hadgraft J, editors. Pharmaceutical Skin Penetration Enhancement. New York, NY: Marcel Dekker; 1993. pp. 57–60.</Citation>
        </Reference>
        <Reference>
          <Citation>Yarosh DB. Topical application of liposomes. J Photochem Photobiol B. 1990;6:445–449. doi: 10.1016/1011-1344(90)85118-G.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/1011-1344(90)85118-G</ArticleId>
            <ArticleId IdType="pubmed">2120411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Batzri S, Korn ED. Single bilayer liposomes prepared without sonication. Biochim Biophys Acta. 1973;298:1015–1019. doi: 10.1016/0005-2736(73)90408-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0005-2736(73)90408-2</ArticleId>
            <ArticleId IdType="pubmed">4738145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagarsenker MS, Londhe VY, Nadkarni GD. Preparation and evaluation of liposomal formulations of tropicamide for ocular delivery. Int J Pharm. 1999;190:63–71. doi: 10.1016/S0378-5173(99)00265-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0378-5173(99)00265-3</ArticleId>
            <ArticleId IdType="pubmed">10528098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elzainy AAW, Gu X, Simons FER, Simons KJ. Effect of different phospholipids on the stability of liposomal formulations containing hydroxyzine. AAPS Pharm Sci. 2002;4:4–4.</Citation>
        </Reference>
        <Reference>
          <Citation>Olfert ED, Cross BM, Mcwilliam AA.  Guide to the Care and Use of Experimental Animals. Ottawa ON, Canada: Canadian Council on Animal Care; 1993. </Citation>
        </Reference>
        <Reference>
          <Citation>Simons FER, Simons KJ, Frith EM. The pharmacokinetics and antihistaminic effects of the H1-receptor antagonist hydroxyzine. J Allergy Clin Immunol. 1984;73:69–75. doi: 10.1016/0091-6749(84)90486-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0091-6749(84)90486-X</ArticleId>
            <ArticleId IdType="pubmed">6141198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watson WTA, Simons KJ, Chen XY, Simons FER. Cetirizine: a pharmacokinetics and pharmacodynamic evaluation in children with seasonal allergic rhinitis. J Allergy Clin Immunol. 1989;84:457–464. doi: 10.1016/0091-6749(89)90358-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0091-6749(89)90358-8</ArticleId>
            <ArticleId IdType="pubmed">2571627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simons FER, Silver NA, Gu X, Simons KJ. Skin concentrations of H1-receptor antagonists. J Allergy Clin Immunol. 2001;107:526–530. doi: 10.1067/mai.2001.113080.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1067/mai.2001.113080</ArticleId>
            <ArticleId IdType="pubmed">11240955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balen GPV, Caron G, Ermondi G, Pagliara A, Grandi T, Bouchard G, Fruttero R, Carrupt P-A, Testa B. Lipophilicity behaviour of the zwitterionic antihistamine cetirizine in phosphatidylcholine liposomes/water systems. Pharm Res. 2001;18:694–701. doi: 10.1023/A:1011049830615.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/A:1011049830615</ArticleId>
            <ArticleId IdType="pubmed">11465428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel HM, Moghimi SM.  Liposomes and the skin permeability barrier. In: Gregoriadis G, Florence AT, Patel HM, editors. Liposomes in Drug Delivery. Chur, Switzerland: Harwood Academic Publishers; 1993. pp. 142–146.</Citation>
        </Reference>
        <Reference>
          <Citation>Mezei M.  Liposomes and the skin. In: Gregoriadis G, Florence AT, Patel HM, editors. Liposomes in Drug Delivery. Chur, Switzerland: Harwood Academic Publishers; 1993. pp. 125–135.</Citation>
        </Reference>
        <Reference>
          <Citation>Simons FER, Silver NA, Gu X, Simons KJ. Clinical pharmacology of H1-antihistamines in the skin. J Allergy Clin Immunol. 2002;110:777–783. doi: 10.1067/mai.2002.129123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1067/mai.2002.129123</ArticleId>
            <ArticleId IdType="pubmed">12417888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rihoux JP. Therapeutic index of H1-antihistamines: example of cetirizine. Ann. Allergy Asthma Immunol. 1999;83:489–491.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10582736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foldvari M, Gesztes A, Mezei M. Dernal drug delivery by liposome encap sulation: clinical and electron microscopic studies. J Microencapsul. 1990;7:479–489. doi: 10.3109/02652049009040470.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/02652049009040470</ArticleId>
            <ArticleId IdType="pubmed">2266473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bashir SJ, Maibach HI.  Cutaneous metabolism during in-vitro percutaneous absorption. In: Bronaugh RL, Kraeling MEK, Yourick J, Hood HL, editors. Topical Absorption of Dermatological Products. New York, NY: Marcel Dekker; 2002. pp. 77–81.</Citation>
        </Reference>
        <Reference>
          <Citation>Wohlarb W, Lasch J. Penetration kinetics of liposomal hydrocortisone in human skin. Dermatologica. 1987;174:18–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3803670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wohlarb W, Lasch J. The effect of liposomal incorporation of topically applied hydrocortisone on its serum concentration and urinary excretion. Dermatol Monatsschr. 1989;175:348–352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2759315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mezei M, Gulasekharam V. Liposomes: a selective drug delivery system for the topical route of administration. 1. Lotion dosage form. Life Sci. 1980;26:1473–1477. doi: 10.1016/0024-3205(80)90268-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0024-3205(80)90268-4</ArticleId>
            <ArticleId IdType="pubmed">6893068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harsanyi BB, Hilchie JC, Mezei M. Liposomes as drug carriers for oral ulcers. J Dent Res. 1986;65:1133–1141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3461030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foong WC, Harsany BB, Mezei M.  Biodisposition and histological evaluation of topically applied retinoic acid in liposomal, cream and gel dosage forms. In: Hanin I, Pepeu G, editors. Phospholipids. New York, NY: Plenum Press; 1990. pp. 279–282.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
